| Rank | Year | |||
|---|---|---|---|---|
| 2000 | 2005 | 2010 | 2015 | |
| Top drugs by frequency of use, n* (%) | ||||
| 1 | APAP, caffeine and codeine 9119 (16.4) | Atorvastatin 18 014 (18.9) | Metformin 26 486 (16.3) | Rosuvastatin 27 452 (15.6) |
| 2 | Amoxicillin 7367 (13.3) | APAP, caffeine and codeine 14 069 (14.8) | Atorvastatin 24 940 (15.4) | Amoxicillin 24 686 (14.0) |
| 3 | Estrogen 7097 (12.8) | Amoxicillin 13 437 (14.1) | Amoxicillin 23 214 (14.3) | Metformin 23 990 (13.6) |
| 4 | Atorvastatin 6293 (11.3) | Metformin 13 321 (14.0) | Rosuvastatin 22 419 (13.8) | Atorvastatin 19 859 (11.3) |
| 5 | Ranitidine 6260 (11.3) | Ramipril 13 207 (13.9) | APAP, caffeine and codeine 18 459 (11.4) | Albuterol 19 571 (11.1) |
| 6 | Albuterol 5575 (10.0) | Albuterol 10 226 (10.7) | Ramipril 17 330 (10.7) | Levothyroxine 16 865 (9.6) |
| 7 | Lorazepam 5427 (9.8) | Hydrochlorothiazide 10 023 (10.5) | Albuterol 17 016 (10.5) | APAP, caffeine and codeine 14 435 (8.2) |
| 8 | Levothyroxine 5283;(9.5) | Levothyroxine 9141 (9.6) | Levothyroxine 15 297 (9.4) | Amlodipine 14 258 (8.1) |
| 9 | Metformin 4862 (8.7) | Lorazepam 8183 (8.6) | Rabeprazole 13 904 (8.6) | Pantoprazole 13 868 (7.9) |
| 10 | Glyburide 4292 (7.7) | Amlodipine 7702 (8.1) | Amlodipine 13 418 (8.3) | Ramipril 12 380 (7.0) |
| Top drugs by total spending, $† (%) | ||||
| 1 | Atorvastatin 2 600 000 (4.0) | Infliximab 10 450 000 (6.1) | Infliximab 31 830 000 (11.3) | Infliximab 55 370 000 (13.3) |
| 2 | Interferon α2b and ribavirin 2 240 000 (3.4) | Atorvastatin 7 900 000 (4.6) | Etanercept 11 070 000 (3.9) | Ledipasvir and sofosbuvir 24 620 000 (5.9) |
| 3 | Interferon β 2 080 000 (3.2) | Interferon β1a 7 000 000 (4.1) | Interferon β1a 9 339 000 (3.3) | Adalimumab 23 520 000 (5.7) |
| 4 | Interferon β1a 2 050 000 (3.1) | Imatinib 4 980 000 (2.9) | Oxycodone 8 180 000 (2.9) | Etanercept 14 340 000 (3.4) |
| 5 | Omeprazole 1 970 000 (3.0) | Etanercept 4 700 000 (2.8) | Adalimumab 8 100 000 (2.9) | Tenofovir 10 900 000 (2.6) |
| 6 | Olanzapine 1 710 000 (2.6) | Olanzapine 3 920 000 (2.3) | Imatinib $6 900 000 (2.5) | Eculizumab 10 040 000 (2.4) |
| 7 | Lamivudine 1 700 000 (2.6) | Lamivudine and zidovudine 3 280 000 (1.9) | Rosuvastatin 6 500 000 (2.3) | Interferon β1a 73 760 000 (1.8) |
| 8 | Nelfinavir 1 420 000 (2.2) | Oxycodone 3 250 000 (1.9) | Atorvastatin 6 420 000 (2.3) | Efavirenz, emtricitabine and tenofovir 71 010 000 (1.7) |
| 9 | Stavudine 1 400 000 (2.1) | Ramipril 3 060 000 (1.8) | Efavirenz, emtricitabine and tenofovir 6 350 000 (2.3) | Sofosbuvir 6 740 000 (1.6) |
| 10 | Lamivudine and zidovudine 1 360 000 (2.1) | Omeprazole 3 040 000 (1.8) | Abacavir and lamivudine 5 000 000 (1.8) | Lenalidomide 6 720 000 (1.6) |
Note: APAP = acetaminophen.*No. of users.†Dollar values reported to the nearest $10 000.